James R. Kasinger - 10 Mar 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: General Counsel and Secretary
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 10 Mar 2026
Net transactions value: -$147,840
Form type: 4
Filing time: 12 Mar 2026, 17:35:06 UTC
Previous filing: 20 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
KASINGER JAMES R.	General Counsel and Secretary	C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	12 Mar 2026	0001708172

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+5,500	+6.5%		90,615	10 Mar 2026	Direct	F1, F2
transaction	CRSP	Common Shares	Sale	$147,840	-2,800	-3.1%	$52.80	87,815	11 Mar 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-5,500	-50%		5,500	10 Mar 2026	Common Shares	5,500		Direct	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
F2	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F4	This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.